Circular mRNA In Vivo CAR-T for Cancer & Autoimmune Diseases
- Sharing innovations in cmCAR and CellectLNP technology enable a differentiable and highly extensible in vivo cell engineering platform
- Revealing how BR101, a bi-specific in vivo CAR-T pipeline based on cmCAR and CellectLNP, exhibits robust and systemic B-cell depletion and immunereset in NHP
- Exploring how an open-label, single-arm clinical trial has been initiated to evaluate safety and efficacy of BR101 in cancer and autoimmune diseases